Quadrivalent influenza vaccine (surface antigen, inactivated, cell-based)

PBAC's latest decision on Quadrivalent influenza vaccine (surface antigen, inactivated, cell-based): Recommended with restriction (2022). Considered for Prevention of seasonal influenza in Aboriginal and Torres Strait Islander people aged ≥5 to <65 years, persons aged ≥5 to <65 years with chronic medical conditions increasing risk of influenza complications, and pregnant women. Children older than 5 years but less than 9 years require 2 doses at least 1 month apart for initial vaccination.

Eligible population

Aboriginal and Torres Strait Islander people aged ≥5 to <65 years, persons aged ≥5 to <65 years with chronic cardiac, respiratory, neurological or other chronic illnesses, and pregnant women aged 5 to <65 years

Therapy area

Vaccines

Line of therapy

First-line

Evidence base

RCT | Registry

Primary endpoint

Surrogate

Pivotal trial size

2,414 patients

Key trials

V130_10 (NCT04074928), Boikos 2020, Divino 2020, Boikos 2021, Krishnarajah 2021, Seqirus 2021, Divino 2021

Comparator

egg-based quadrivalent influenza vaccine (QIVe)

Economic model

CEA

ICER note

The document indicates the sponsor used price and cost-effectiveness claims but does not explicitly state a numeric ICER in the public text. The submission is described as being based on a cost-effectiveness analysis, but the specific ICER value is not disclosed in this PSD.

Similar precedents

• Cell-cultured quadrivalent influenza vaccine (surface antigen, inactivated)
  similarity 0.93
• Quadrivalent influenza vaccine
  similarity 0.82
• Quadrivalent influenza vaccine (split virion, inactivated)
  similarity 0.82
• Inactivated quadrivalent influenza vaccine (split virion)
  similarity 0.80
• Inactivated quadrivalent influenza vaccine
  similarity 0.79
• Quadrivalent recombinant influenza vaccine
  similarity 0.78